Breaking News
Get 45% Off 0
Selloff or market correction? Either way, here's what to do next
See Overvalued Stocks

Zacks Investment Research Zacks Investment Research

Zacks Investment Research's Opinion & Analysis.
Featured here: a complete archive of all posts and research produced by Zacks Investment Research, including current material.
Is it the Right Time to Invest in Minimum Volatility ETFs? By Zacks Investment Research - May 22, 2020

The coronavirus continues to spread across the United States, with at least 1.5 million cases confirmed and the death toll rising to more than 94,000, according to Johns Hopkins University. However,...

5 Reasons to Add Atmos Energy (ATO) to Your Portfolio Now By Zacks Investment Research - May 22, 2020

Atmos Energy (NYSE:ATO)’s ATO earnings estimates have been revised upward over the past 60 days, reflecting analysts’ optimism surrounding the stock. The Zacks Consensus Estimate for...

K vs. LW: Which Stock Should Value Investors Buy Now? By Zacks Investment Research - May 21, 2020

Investors interested in stocks from the Food - Miscellaneous sector have probably already heard of Kellogg (K) and Lamb Weston (LW). But which of these two companies is the best option for those...

A Familiar Foe Awakens By Zacks Investment Research - May 21, 2020

Hey everybody, Dave Bartosiak here filling in for Jim “The Count” Giaquinto and yes, everyone is getting a nickname today. Jim will be back with you tomorrow. Hopefully he’ll...

Why IVERIC bio (ISEE) Stock Might be a Great Pick By Zacks Investment Research - May 21, 2020

One stock that might be an intriguing choice for investors right now is IVERIC bio (NASDAQ:ISEE), Inc. ISEE. This is because this security in the Medical - Biomedical and Genetics space is seeing...

SELECT INT CONC (SIC) Reports Q1 Loss, Misses Revenue Estimates By Zacks Investment Research - May 21, 2020

SELECT INT CONC (SIC) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to break-even earnings per share a year ago. These figures...

Lions Gate Entertainment (LGF.A) Matches Q4 Earnings Estimates By Zacks Investment Research - May 21, 2020

Lions Gate Entertainment (LGF.A) came out with quarterly earnings of $0.21 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.11 per share a year ago. These figures...

Gilead, Galapagos Announce Positive Data on Inflammatory Drug By Zacks Investment Research - May 21, 2020

Gilead Sciences (NASDAQ:GILD), Inc. GILD and partner Galapagos (NASDAQ:GLPG) NV GLPG announced positive topline results from a late-stage study on its investigational, oral, once-daily, selective JAK1...

AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer By Zacks Investment Research - May 21, 2020

AstraZeneca (NYSE:AZN) AZN and partner Merck MRK announced that the FDA has approved their PARP inhibitor Lynparza for the fourth cancer type — prostate cancer. The FDA approved Lynparza for the...

Continue with Apple
Continue with Google
or
Sign up with Email